FinscoFinsco

IRadimed (US.IRMD)

Capital Allocation Audit · Period: 2012 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.IRMD · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion93.6%↑
ROE10.8%→
Cash Conversion128.9%↑
D/E Ratio0.00↓
Gross Margin75.3%→
US.IRMD (IRadimed) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    93.6%    ↑
ROE               10.8%    →
Cash Conversion  128.9%    ↑
D/E Ratio          0.00    ↓
Gross Margin      75.3%    →
Key Metrics
US.IRMD (IRadimed) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 93.6% ↑
ROE 10.8% →
Cash Conversion 128.9% ↑
D/E Ratio 0.00 ↓
Gross Margin 75.3% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies